Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Morgan Stanley ($MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

Its shares have declined by 50% over this period. But Pfizer's path to a rebound (unlike Teladoc's) seems clear. Even aside ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both numbers came in well above expectations, with diluted EPS $0.20 higher than ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Pfizer Inc (Symbol: PFE) were yielding above the 7% mark based on its quarterly dividend (annualized to ...

3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share ...

Diluted earnings and revenue smashed through Wall Street consensus estimates. Management raised its full-year earnings guidance for 2025. Pfizer is starting to execute on its turnaround plan and drug ...